Tvardi Therapeutics is trading 5.26% up at $1.40, with the cause of the September 29, 2026 move unclear. - The latest company news located was September 24 preclinical data on its STAT3 inhibitor; no September 29 investor-relations release is listed. - Major indices were down less than 0.5%, offering no clear market-driven explanation for the gain.